{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:02:25Z","timestamp":1785798145932,"version":"3.56.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,6]]},"DOI":"10.7759\/cureus.23901","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T05:52:27Z","timestamp":1649310747000},"source":"Crossref","is-referenced-by-count":4,"title":["Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers"],"prefix":"10.7759","author":[{"given":"Sanjana","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zineb","family":"Barkhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Elmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Satish Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Sree","family":"Pugalenthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahlika","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/09540261.2013.852971","article-title":"A review of clinical aspects of breast cancer","volume":"26","author":"Libson S","year":"2014","unstructured":"Libson S, Lippman M. A review of clinical aspects of breast cancer. Int Rev Psychiatry. 2014, 26:4-15. 10.3109\/09540261.2013.852971","journal-title":"Int Rev Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5603\/GP.2016.0062","article-title":"Breast cancer in young women","volume":"87","author":"Radecka B","year":"2016","unstructured":"Radecka B, Litwiniuk M. Breast cancer in young women. Ginekol Pol. 2016, 87:659-63. 10.5603\/GP.2016.0062","journal-title":"Ginekol Pol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20134","article-title":"Breast cancer statistics, 2011","volume":"61","author":"DeSantis C","year":"2011","unstructured":"DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011, 61:409-18. 10.3322\/caac.20134","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson GL","year":"2012","unstructured":"Anderson GL, Chlebowski RT, Aragaki AK, et al.. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012, 13:476-86. 10.1016\/S1470-2045(12)70075-X","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.1.25","article-title":"Breast cancer after treatment of Hodgkin's disease","volume":"85","author":"Hancock SL","year":"1993","unstructured":"Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993, 85:25-31. 10.1093\/jnci\/85.1.25","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2000.8110","article-title":"Breast cancer: risk factors, screening, and prevention","volume":"16","author":"Gross RE","year":"2000","unstructured":"Gross RE. Breast cancer: risk factors, screening, and prevention. Semin Oncol Nurs. 2000, 16:176-84. 10.1053\/sonc.2000.8110","journal-title":"Semin Oncol Nurs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan D","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011, 144:646-74. 10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000249","article-title":"CDK4\/6 inhibitors in breast cancer","volume":"26","author":"Dukelow T","year":"2015","unstructured":"Dukelow T, Kishan D, Khasraw M, Murphy CG. CDK4\/6 inhibitors in breast cancer. Anticancer Drugs. 2015, 26:797-806. 10.1097\/CAD.0000000000000249","journal-title":"Anticancer Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490:61-70. 10.1038\/nature11412","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186479","article-title":"Targeting cell cycle in breast cancer: CDK4\/6 inhibitors","volume":"21","author":"Piezzo M","year":"2020","unstructured":"Piezzo M, Cocco S, Caputo R, et al.. Targeting cell cycle in breast cancer: CDK4\/6 inhibitors. Int J Mol Sci. 2020, 21:10.3390\/ijms21186479","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s1534-5807(04)00067-x","article-title":"Cell cycle development","volume":"6","author":"Coffman JA","year":"2004","unstructured":"Coffman JA. Cell cycle development. Dev Cell. 2004, 6:321-7. 10.1016\/s1534-5807(04)00067-x","journal-title":"Dev Cell"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2016.01.007","article-title":"Unraveling cell-cycle dynamics in cancer","volume":"2","author":"Kar S","year":"2016","unstructured":"Kar S. Unraveling cell-cycle dynamics in cancer. Cell Syst. 2016, 2:8-10. 10.1016\/j.cels.2016.01.007","journal-title":"Cell Syst"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-857-9:113","article-title":"The mammalian cell cycle: an overview","volume":"296","author":"Harper JV","year":"2005","unstructured":"Harper JV, Brooks G. The mammalian cell cycle: an overview. Methods Mol Biol. 2005, 296:113-53. 10.1385\/1-59259-857-9:113","journal-title":"Methods Mol Biol"},{"key":"ref14","article-title":"Genesis, modulation, and regeneration of skeletal muscle","author":"Alberts B","year":"2002","unstructured":"Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Genesis, modulation, and regeneration of skeletal muscle. Molecular biology of the cell. 4th edition. Garland Science, New York; 2002."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81684-0","article-title":"A long twentieth century of the cell cycle and beyond","volume":"7","author":"Nurse P","year":"2000","unstructured":"Nurse P. A long twentieth century of the cell cycle and beyond. Cell. 2000, 7:71-8. 10.1016\/s0092-8674(00)81684-0","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90385-2","article-title":"The retinoblastoma protein and cell cycle control","volume":"81","author":"Weinberg RA","year":"1995","unstructured":"Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995, 81:323-30. 10.1016\/0092-8674(95)90385-2","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1101\/gad.7.3.331","article-title":"Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4","volume":"7","author":"Kato J","year":"1993","unstructured":"Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993, 7:331-42. 10.1101\/gad.7.3.331","journal-title":"Genes Dev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2399","article-title":"Cellular mechanisms of tumour suppression by the retinoblastoma gene","volume":"8","author":"Burkhart DL","year":"2008","unstructured":"Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008, 8:671-82. 10.1038\/nrc2399","journal-title":"Nat Rev Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1999.2640","article-title":"Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors","volume":"287","author":"Pavletich NP","year":"1999","unstructured":"Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999, 287:821-8. 10.1006\/jmbi.1999.2640","journal-title":"J Mol Biol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1997.3824","article-title":"The tumor suppressor protein p16INK4a","volume":"237","author":"Serrano M","year":"1997","unstructured":"Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997, 237:7-13. 10.1006\/excr.1997.3824","journal-title":"Exp Cell Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.1995.0014","article-title":"Regulation of the cell cycle by viral oncoproteins","volume":"6","author":"Vousden KH","year":"1995","unstructured":"Vousden KH. Regulation of the cell cycle by viral oncoproteins. Semin Cancer Biol. 1995, 6:109-16. 10.1006\/scbi.1995.0014","journal-title":"Semin Cancer Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future","volume":"395","author":"Spring LM","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020, 395:817-27. 10.1016\/S0140-6736(20)30165-3","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs002","article-title":"Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy","volume":"104","author":"Roberts PJ","year":"2012","unstructured":"Roberts PJ, Bisi JE, Strum JC, et al.. Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012, 104:476-87. 10.1093\/jnci\/djs002","journal-title":"J Natl Cancer Inst"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689680","article-title":"Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells","volume":"31","author":"Watts CK","year":"1994","unstructured":"Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1994, 31:95-105. 10.1007\/BF00689680","journal-title":"Breast Cancer Res Treat"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1684559","article-title":"CDK4\/6 inhibitors in breast cancer - from in\u00a0vitro models to clinical trials","volume":"59","author":"Saleh L","year":"2020","unstructured":"Saleh L, Wilson C, Holen I. CDK4\/6 inhibitors in breast cancer - from in\u00a0vitro models to clinical trials. Acta Oncol. 2020, 59:219-32. 10.1080\/0284186X.2019.1684559","journal-title":"Acta Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar U","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015, 14:130-46. 10.1038\/nrd4504","journal-title":"Nat Rev Drug Discov"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/jat.1177","article-title":"Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors","volume":"27","author":"Jessen BA","year":"2007","unstructured":"Jessen BA, Lee L, Koudriakova T, et al.. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol. 2007, 27:133-42. 10.1002\/jat.1177","journal-title":"J Appl Toxicol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0443","article-title":"The role of CDK4\/6 inhibition in breast cancer","volume":"20","author":"Murphy CG","year":"2015","unstructured":"Murphy CG, Dickler MN. The role of CDK4\/6 inhibition in breast cancer. Oncologist. 2015, 20:483-90. 10.1634\/theoncologist.2014-0443","journal-title":"Oncologist"},{"key":"ref29","unstructured":"Pfizer. Pfizer receives US FDA accelerated approval of IBRANCE\u00d2 (palbociclib). (2015). Accessed: February 3, 2015: http:\/\/www.pfizer.com."},{"key":"ref30","unstructured":"PubChem. Compound summary: Palbociclib. (2006). http:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Palbociclib."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn RS","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, et al.. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11:R77. 10.1186\/bcr2419","journal-title":"Breast Cancer Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn RS","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, et al.. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015, 16:25-35. 10.1016\/S1470-2045(14)71159-3","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn RS","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, et al.. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016, 375:1925-36. 10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner NC","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, et al.. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015, 373:209-19. 10.1056\/NEJMoa1505270","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA- 3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli M","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, et al.. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA- 3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016, 17:425-39. 10.1016\/S1470-2045(15)00613-0","journal-title":"Lancet Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS13-OT2-6-01","article-title":"Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4\/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TREnd trial)","volume":"73","author":"Malorni L","year":"2013","unstructured":"Malorni L, Sanna G, Pestrin M, et al.. Abstract OT2-6-01: Phase 2 study of palbociclib (CDK 4\/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TREnd trial). Cancer Res. 2013, 73:10.1158\/0008-5472.SABCS13-OT2-6-01","journal-title":"Cancer Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS13-OT2-6-11","article-title":"Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4\/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78\/BIG1-13)","volume":"73","author":"von Minckwitz G","year":"2013","unstructured":"von Minckwitz G, Bear H, Bonnefoi H, et al.. Abstract OT2-6-11: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4\/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78\/BIG1-13). Cancer Res. 2013, 73:10.1158\/0008-5472.SABCS13-OT2-6-11","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz198","article-title":"A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma","volume":"30","author":"Mayer EL","year":"2019","unstructured":"Mayer EL, DeMichele A, Rugo HS, et al.. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019, 30:1514-20. 10.1093\/annonc\/mdz198","journal-title":"Ann Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-13-PR02","article-title":"Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4\/6- Reactivating Rb in cancer","volume":"12","author":"Kim S","year":"2013","unstructured":"Kim S, Loo A, Chopra R, et al.. Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4\/6- Reactivating Rb in cancer. Mol Cancer Ther. 2013, 12:10.1158\/1535-7163.TARG-13-PR02","journal-title":"Mol Cancer Ther"},{"key":"ref40","unstructured":"PubChem. Compound summary: Ribociclib. (2010). http:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ribociclib."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0816","article-title":"Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment","volume":"21","author":"VanArsdale T","year":"2015","unstructured":"VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment. Clin Cancer Res. 2015, 21:2905-10. 10.1158\/1078-0432.CCR-14-0816","journal-title":"Clin Cancer Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2369","article-title":"FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","volume":"24","author":"Shah A","year":"2018","unstructured":"Shah A, Bloomquist E, Tang S, et al.. FDA approval: ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Clin Cancer Res. 2018, 24:2999-3004. 10.1158\/1078-0432.CCR-17-2369","journal-title":"Clin Cancer Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S150540","article-title":"Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+\/HER2- metastatic breast cancer: a focus on ribociclib","volume":"9","author":"Edessa D","year":"2017","unstructured":"Edessa D, Sisay M. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+\/HER2- metastatic breast cancer: a focus on ribociclib. Breast Cancer (Dove Med Press). 2017, 9:567-79. 10.2147\/BCTT.S150540","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.05.100","article-title":"Cyclin dependent kinase (CDK) inhibitors as anticancer drugs","volume":"25","author":"S\u00e1nchez-Mart\u00ednez C","year":"2015","unstructured":"S\u00e1nchez-Mart\u00ednez C, Gelbert LM, Lallena MJ, de Dios A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg Med Chem Lett. 2015, 25:3420-35. 10.1016\/j.bmcl.2015.05.100","journal-title":"Bioorg Med Chem Lett"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski R Jr","year":"2016","unstructured":"Roskoski R Jr. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res. 2016, 107:249-75. 10.1016\/j.phrs.2016.03.012","journal-title":"Pharmacol Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi GN","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al.. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016, 375:1738-48. 10.1056\/NEJMoa1609709","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon DJ","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, et al.. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018, 36:2465-72. 10.1200\/JCO.2018.78.9909","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy D","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, et al.. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018, 19:904-15. 10.1016\/S1470-2045(18)30292-4","journal-title":"Lancet Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018817904","article-title":"Ribociclib in HR+\/HER2- advanced or metastatic breast cancer patients","volume":"53","author":"Rascon K","year":"2019","unstructured":"Rascon K, Flajc G, De Angelis C, Liu X, Trivedi MV, Ekinci E. Ribociclib in HR+\/HER2- advanced or metastatic breast cancer patients. Ann Pharmacother. 2019, 53:501-9. 10.1177\/1060028018817904","journal-title":"Ann Pharmacother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1503484","article-title":"Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+\/HER2- advanced or metastatic breast cancer","volume":"34","author":"Mistry R","year":"2018","unstructured":"Mistry R, Suri G, Young K, et al.. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+\/HER2- advanced or metastatic breast cancer. Curr Med Res Opin. 2018, 34:2143-50. 10.1080\/03007995.2018.1503484","journal-title":"Curr Med Res Opin"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2019.11.003","article-title":"Ribociclib-associated vortex keratopathy","volume":"55","author":"Saeed D","year":"2020","unstructured":"Saeed D, Hussain A. Ribociclib-associated vortex keratopathy. Can J Ophthalmol. 2020, 55:e140-2. 10.1016\/j.jcjo.2019.11.003","journal-title":"Can J Ophthalmol"},{"key":"ref52","unstructured":"PubChem. Compound summary: Abemaciclib. (2006). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Abemaciclib."},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary B","year":"2016","unstructured":"O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol. 2016, 13:417-30. 10.1038\/nrclinonc.2016.26","journal-title":"Nat Rev Clin Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer","volume":"23","author":"Dickler MN","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, et al.. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer. Clin Cancer Res. 2017, 23:5218-24. 10.1158\/1078-0432.CCR-17-0754","journal-title":"Clin Cancer Res"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge GW Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, et al.. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017, 35:2875-84. 10.1200\/JCO.2017.73.7585","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz MP","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, et al.. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017, 35:3638-46. 10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.05.001","article-title":"Selective inhibition of CDK4\/6: a safe and effective strategy for developing anticancer drugs","volume":"11","author":"Yuan K","year":"2021","unstructured":"Yuan K, Wang X, Dong H, Min W, Hao H, Yang P. Selective inhibition of CDK4\/6: a safe and effective strategy for developing anticancer drugs. Acta Pharm Sin B. 2021, 11:30-54. 10.1016\/j.apsb.2020.05.001","journal-title":"Acta Pharm Sin B"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.512","article-title":"229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+\/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): final results of the PEARL study","volume":"32","author":"Martin Jimenez M","year":"2021","unstructured":"Martin Jimenez M, Zielinski C, Ruiz-Borrego M, et al.. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+\/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): final results of the PEARL study. Ann Oncol. 2021, 32:457-8. 10.1016\/j.annonc.2021.08.512","journal-title":"Ann Oncol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0651-4","article-title":"The role of CDK4\/6 inhibitors in breast cancer","volume":"20","author":"Murphy CG","year":"2019","unstructured":"Murphy CG. The role of CDK4\/6 inhibitors in breast cancer. Curr Treat Options Oncol. 2019, 20:52. 10.1007\/s11864-019-0651-4","journal-title":"Curr Treat Options Oncol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel S","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, et al.. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017, 548:471-5. 10.1038\/nature23465","journal-title":"Nature"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng J","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, et al.. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018, 8:216-33. 10.1158\/2159-8290.CD-17-0915","journal-title":"Cancer Discov"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga J","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, et al.. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012, 366:520-9. 10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2114","article-title":"Phase I\/II trial of exemestane, ribociclib, and everolimus in women with HR+\/HER2- advanced breast cancer after progression on CDK4\/6 inhibitors (TRINITI-1)","volume":"27","author":"Bardia A","year":"2021","unstructured":"Bardia A, Hurvitz SA, DeMichele A, et al.. Phase I\/II trial of exemestane, ribociclib, and everolimus in women with HR+\/HER2- advanced breast cancer after progression on CDK4\/6 inhibitors (TRINITI-1). Clin Cancer Res. 2021, 27:4177-85. 10.1158\/1078-0432.CCR-20-2114","journal-title":"Clin Cancer Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu MT","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, et al.. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016, 76:2301-13. 10.1158\/0008-5472.CAN-15-0728","journal-title":"Cancer Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0963","article-title":"Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells","volume":"11","author":"Caldon CE","year":"2012","unstructured":"Caldon CE, Sergio CM, Kang J, et al.. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther. 2012, 11:1488-99. 10.1158\/1535-7163.MCT-11-0963","journal-title":"Mol Cancer Ther"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang C","year":"2017","unstructured":"Yang C, Li Z, Bhatt T, et al.. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017, 36:2255-64. 10.1038\/onc.2016.379","journal-title":"Oncogene"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander SA","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, et al.. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020, 10:1174-93. 10.1158\/2159-8290.CD-19-1390","journal-title":"Cancer Discov"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2653","article-title":"Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer","volume":"77","author":"Jansen VM","year":"2017","unstructured":"Jansen VM, Bhola NE, Bauer JA, et al.. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer. Cancer Res. 2017, 77:2488-99. 10.1158\/0008-5472.CAN-16-2653","journal-title":"Cancer Res"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00666","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice","volume":"9","author":"McCartney A","year":"2019","unstructured":"McCartney A, Migliaccio I, Bonechi M, et al.. Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice. Front Oncol. 2019, 9:666. 10.3389\/fonc.2019.00666","journal-title":"Front Oncol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0234","article-title":"Future perspectives and challenges with CDK4\/6 inhibitors in hormone receptor-positive metastatic breast cancer","volume":"16","author":"Bayraktar S","year":"2020","unstructured":"Bayraktar S, Batoo S, Al-Hattab E, Basu S, Okuno S, Gl\u00fcck S. Future perspectives and challenges with CDK4\/6 inhibitors in hormone receptor-positive metastatic breast cancer. Future Oncol. 2020, 16:2661-72. 10.2217\/fon-2020-0234","journal-title":"Future Oncol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain SM","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, et al.. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015, 372:724-34. 10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.2174\/9781681087016118090008","article-title":"The prospects of CDK targeting and clinical application of cdk inhibitors in cancer","author":"Gangopadhyay A","year":"2018","unstructured":"Gangopadhyay A, Gangopadhyay A. The prospects of CDK targeting and clinical application of cdk inhibitors in cancer. Frontiers in Anti-Cancer Drug Discovery. 2018. 9:234. 10.2174\/9781681087016118090008"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"Neopalana: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume":"23","author":"Ma CX","year":"2017","unstructured":"Ma CX, Gao F, Luo J, et al.. Neopalana: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017, 23:4055-65. 10.1158\/1078-0432.CCR-16-3206","journal-title":"Clin Cancer Res"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607012","article-title":"CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation","volume":"9","author":"Dall'Acqua A","year":"2017","unstructured":"Dall'Acqua A, Sonego M, Pellizzari I, et al.. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med. 2017, 9:1415-33. 10.15252\/emmm.201607012","journal-title":"EMBO Mol Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.161281798","article-title":"ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation","volume":"98","author":"Nghiem P","year":"2001","unstructured":"Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A. 2001, 98:9092-7. 10.1073\/pnas.161281798","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.05.681","article-title":"Immunotherapy for platinum-resistant ovarian cancer","volume":"158","author":"Bogani G","year":"2020","unstructured":"Bogani G, Lopez S, Mantiero M, et al.. Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. 2020, 158:484-8. 10.1016\/j.ygyno.2020.05.681","journal-title":"Gynecol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/92663-cyclin-dependent-kinase-4-and-6-inhibitors-a-quantum-leap-in-the-treatment-of-advanced-breast-cancers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:09Z","timestamp":1707507909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/92663-cyclin-dependent-kinase-4-and-6-inhibitors-a-quantum-leap-in-the-treatment-of-advanced-breast-cancers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":76,"URL":"https:\/\/doi.org\/10.7759\/cureus.23901","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,6]]}}}